Brokers Set Expectations for electroCore FY2025 Earnings

electroCore, Inc. (NASDAQ:ECOR) – Research analysts at Brookline Capital Management issued their FY2025 earnings per share (EPS) estimates for shares of electroCore in a research report issued on Tuesday, February 3rd. Brookline Capital Management analyst F. Ahmed forecasts that the company will earn ($1.70) per share for the year. Brookline Capital Management currently has a “Strong-Buy” rating on the stock. The consensus estimate for electroCore’s current full-year earnings is ($1.49) per share. Brookline Capital Management also issued estimates for electroCore’s Q4 2025 earnings at ($0.39) EPS, Q1 2026 earnings at ($0.33) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.53) EPS.

electroCore (NASDAQ:ECOR) last released its earnings results on Wednesday, November 5th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.07). electroCore had a negative net margin of 47.46% and a negative return on equity of 447.87%. The business had revenue of $8.69 million during the quarter, compared to analyst estimates of $7.84 million.

Several other equities research analysts have also recently issued reports on the stock. Wall Street Zen raised shares of electroCore from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Zacks Research downgraded shares of electroCore from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of electroCore in a research note on Monday, December 29th. Finally, HC Wainwright dropped their price objective on electroCore from $25.00 to $18.00 and set a “buy” rating for the company in a report on Monday, January 26th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $22.00.

electroCore Trading Down 8.6%

Shares of NASDAQ:ECOR opened at $5.07 on Friday. The firm has a market cap of $40.56 million, a price-to-earnings ratio of -2.96 and a beta of 0.48. The stock’s 50-day moving average price is $5.58 and its two-hundred day moving average price is $5.44. electroCore has a 12-month low of $4.16 and a 12-month high of $19.49.

Institutional Investors Weigh In On electroCore

Several large investors have recently made changes to their positions in the business. FNY Investment Advisers LLC purchased a new position in shares of electroCore in the 4th quarter valued at $82,000. Cubist Systematic Strategies LLC purchased a new position in electroCore in the first quarter valued at about $153,000. Two Sigma Investments LP lifted its stake in shares of electroCore by 20.8% during the third quarter. Two Sigma Investments LP now owns 24,603 shares of the company’s stock worth $122,000 after purchasing an additional 4,231 shares in the last quarter. Jane Street Group LLC boosted its position in shares of electroCore by 114.4% in the first quarter. Jane Street Group LLC now owns 36,726 shares of the company’s stock worth $246,000 after buying an additional 19,599 shares during the period. Finally, Jaffetilchin Investment Partners LLC grew its stake in shares of electroCore by 26.7% in the second quarter. Jaffetilchin Investment Partners LLC now owns 41,783 shares of the company’s stock valued at $221,000 after buying an additional 8,800 shares in the last quarter. Institutional investors and hedge funds own 26.74% of the company’s stock.

electroCore Company Profile

electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.

The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.